Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 17.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 157,774 shares of the company's stock after purchasing an additional 23,631 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Moderna were worth $10,544,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna during the 2nd quarter valued at $26,000. Family Firm Inc. purchased a new stake in Moderna during the second quarter valued at about $33,000. Bank & Trust Co purchased a new position in shares of Moderna in the 2nd quarter worth about $36,000. Hanseatic Management Services Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at about $48,000. Finally, Plato Investment Management Ltd grew its holdings in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock worth $49,000 after purchasing an additional 288 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,856 shares of company stock worth $149,374. 15.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently commented on the stock. The Goldman Sachs Group cut their price target on shares of Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a report on Monday, September 16th. JPMorgan Chase & Co. cut their target price on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a research note on Tuesday, November 26th. HSBC raised shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target for the company in a research report on Monday, November 18th. Leerink Partners reduced their price objective on Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a research note on Tuesday, September 17th. Finally, TD Cowen lowered their target price on Moderna from $70.00 to $60.00 and set a "hold" rating for the company in a research note on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $83.33.

Moderna Stock Performance

Moderna stock traded up $1.20 during mid-day trading on Monday, reaching $44.26. The company's stock had a trading volume of 6,826,035 shares, compared to its average volume of 4,900,981. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The business has a 50 day moving average price of $52.38 and a 200-day moving average price of $90.84. The firm has a market cap of $17.03 billion, a price-to-earnings ratio of -7.40 and a beta of 1.69.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company's quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.39) EPS. Sell-side analysts predict that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.